focus -WSS

focus

author：comprehensive 2025-09-29 21:26:32 - browse：84775

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Why Novartis is going to walk from its acquisition of MorphoSys

focus

WSS

Gene therapy for Afghan refugees’ infant will be fully covered

Undocumented workers face uncertainty as immigration law takes effect in Florida

Security flaws in third

AI gets buy

AstraZeneca lung cancer study comes in below expectations

Medicare Advantage plans can’t deny care with AI, CMS warns

hotspot

focus

hotspot

The high cost of giving birth even with insurance

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

BioMarin wins approval for gene therapy to treat hemophilia A

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

The cancer drug shortage isn’t new — and neither are the solutions

A single Democrat is willing to weaken Medicare negotiation power

Peter Hotez and the public health issue of online harassment

Malaria cases in Florida and Texas: Here’s what you need to know

Dexcom's push to bring CGM to type 2 diabetes patients

entertainment

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Lupron, used to halt puberty in children, may cause lasting health problems

UpToDate has a racism problem: Dr. Stanley Goldfarb

UpToDate has a racism problem: Dr. Stanley Goldfarb

AstraZeneca lung cancer study comes in below expectations

Lupron, used to halt puberty in children, may cause lasting health problems

explore

entertainment

focus

leisure time